Headquartered in Indianapolis, IN Fiscal year ends December NYSE: LLY lilly.com
Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, and commercializing medicines across several therapeutic areas including diabetes, obesity, immunology, oncology, and neuroscience. The company's portfolio is anchored by its incretin-based medicines Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity), which together represent the majority of revenue. Lilly's Key Products also include Ebglyss (lebrikizumab for atopic dermatitis), Jaypirca (pirtobrutinib for hematologic cancers), Kisunla (donanemab for Alzheimer's disease), Omvoh (mirikizumab for ulcerative colitis), Inluriyo, and Foundayo (orforglipron, an oral GLP-1 for type 2 diabetes). The company maintains a deep pipeline highlighted by retatrutide, a next-generation GLP-1/GIP/glucagon triple agonist for obesity and related comorbidities, and olomorasib for KRAS-mutant cancers. Lilly operates globally, with significant revenue from the United States, Europe, Japan, and China, and collaborates with Boehringer Ingelheim on Jardiance. The company is actively expanding its manufacturing footprint, particularly in Indiana, and has pursued an aggressive business development strategy through multiple acquisitions spanning genetic medicines, oncology, sleep-wake disorders, and infectious diseases. Updated
A 3.7% slide to $1,135.59 shaves tens of billions off a trillion-dollar market cap in a single session, a rare swing for a megacap this size. Whether it holds above the open at $1,179.02 by the close is the thing to keep an eye on.
Eli Lilly's two blockbuster drug approvals that transformed the company into a pharmaceutical giant turned out to be the worst moments to buy the stock. The entry point that crushed every other…
Trey Thoelcke The 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,359.12 over the next 12 months. With the stock at $1,142.85, that implies 18.92% upside. Lilly wins…
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only…
Roughly 700,000 seniors have started GLP-1 obesity treatments since Medicare’s Bridge program launched July 1, 2026, according to Eli Lilly (NYSE:LLY | LLY Price Prediction) CEO David Ricks. Eligible beneficiaries pay $50…
Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that…
A pipefitter switching contractors during construction of a massive new pharmaceutical plant could walk away from tax season with a surprise windfall, and most workers in the same situation never even realize…
Gerelyn Terzo Citigroup sees a path to 35% gains from here, but Eli Lilly's pricing headwinds, a slow oral GLP-1 launch, and a rival in freefall raise a real question about whether this pause…
The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the needle on a stock already up 60% and closing in…
Omor Ibne Ehsan Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most…
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether…
Ken Langone, chairman and president of Invemed Associates and a co-founder of Home Depot (NYSE:HD | HD Price Prediction), used a CNBC Squawk Box appearance on September 22, 2026 to say that…
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the…
Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points to something Wall Street may be mispricing entirely.
Vandita Jadeja NVIDIA and Eli Lilly both shattered expectations this quarter, but picking the better stock for the next decade means choosing between two very different growth machines at very different levels of risk.
Novo Nordisk (NYSE:NVO | NVO Price Prediction) laid out its long-term growth strategy at a capital markets day in London Monday morning, and the plan didn’t calm investor worries about the company’s…
Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, and commercializing medicines across several therapeutic areas including diabetes, obesity, immunology, oncology, and neuroscience.
24/7 Wall St.'s 12-month price target for LLY is $1,370.09, rated Buy. The Wall Street consensus target is $1,328.83. LLY price prediction →
